Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products for the treatment of diabetes and cardiovascular-based diseases in China. More Details
Flawless balance sheet with solid track record.
Share Price & News
How has Tonghua Dongbao Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 600867 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 600867's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 600867 underperformed the CN Pharmaceuticals industry which returned 10.4% over the past year.
Return vs Market: 600867 underperformed the CN Market which returned 25% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Tonghua Dongbao Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Tonghua Dongbao Pharmaceutical undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 600867 (CN¥12.18) is trading above our estimate of fair value (CN¥8.02)
Significantly Below Fair Value: 600867 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 600867 is good value based on its PE Ratio (26.5x) compared to the CN Pharmaceuticals industry average (31.9x).
PE vs Market: 600867 is good value based on its PE Ratio (26.5x) compared to the CN market (33.6x).
Price to Earnings Growth Ratio
PEG Ratio: 600867 is poor value based on its PEG Ratio (1.5x)
Price to Book Ratio
PB vs Industry: 600867 is overvalued based on its PB Ratio (4.7x) compared to the CN Pharmaceuticals industry average (2.7x).
How is Tonghua Dongbao Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600867's forecast earnings growth (17.3% per year) is above the savings rate (3.3%).
Earnings vs Market: 600867's earnings (17.3% per year) are forecast to grow slower than the CN market (22.9% per year).
High Growth Earnings: 600867's earnings are forecast to grow, but not significantly.
Revenue vs Market: 600867's revenue (16.1% per year) is forecast to grow slower than the CN market (17.7% per year).
High Growth Revenue: 600867's revenue (16.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600867's Return on Equity is forecast to be high in 3 years time (23.2%)
How has Tonghua Dongbao Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 600867 has high quality earnings.
Growing Profit Margin: 600867's current net profit margins (32.2%) are higher than last year (29.2%).
Past Earnings Growth Analysis
Earnings Trend: 600867's earnings have grown by 9% per year over the past 5 years.
Accelerating Growth: 600867's earnings growth over the past year (14.6%) exceeds its 5-year average (9% per year).
Earnings vs Industry: 600867 earnings growth over the past year (14.6%) exceeded the Pharmaceuticals industry 10.3%.
Return on Equity
High ROE: 600867's Return on Equity (17.6%) is considered low.
How is Tonghua Dongbao Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: 600867's short term assets (CN¥1.8B) exceed its short term liabilities (CN¥129.0M).
Long Term Liabilities: 600867's short term assets (CN¥1.8B) exceed its long term liabilities (CN¥77.2M).
Debt to Equity History and Analysis
Debt Level: 600867 is debt free.
Reducing Debt: 600867 has no debt compared to 5 years ago when its debt to equity ratio was 36.9%.
Debt Coverage: 600867 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: 600867 has no debt, therefore coverage of interest payments is not a concern.
What is Tonghua Dongbao Pharmaceutical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 600867's dividend (1.64%) is higher than the bottom 25% of dividend payers in the CN market (0.44%).
High Dividend: 600867's dividend (1.64%) is low compared to the top 25% of dividend payers in the CN market (1.79%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, 600867 has been paying a dividend for less than 10 years.
Growing Dividend: 600867's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (43.5%), 600867's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: 600867's dividends in 3 years are forecast to be well covered by earnings (32.7% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Sheng Leng Chun (46 yo)
Mr. Chun Sheng Leng is the Chairman and General Manager at Tonghua Dongbao Pharmaceutical Co., Ltd. and served as its Deputy General Manager since March 27, 2014. and has been its Director since March 27, ...
Experienced Management: 600867's management team is seasoned and experienced (7.1 years average tenure).
Experienced Board: 600867's board of directors are considered experienced (7.1 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Tonghua Dongbao Pharmaceutical Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Tonghua Dongbao Pharmaceutical Co., Ltd.
- Ticker: 600867
- Exchange: SHSE
- Founded: 1985
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥24.623b
- Shares outstanding: 2.02b
- Website: https://www.thdb.com
Number of Employees
- Tonghua Dongbao Pharmaceutical Co., Ltd.
- Dongbao New Village
- Tonghua County
- Jilin Province
Tonghua Dongbao Pharmaceutical Co., Ltd. researches and develops, manufactures, and sells pharmaceutical products for the treatment of diabetes and cardiovascular-based diseases in China. The company opera...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/17 09:04|
|End of Day Share Price||2021/04/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.